The beginning of the end: Eliquis sales forecast to plummet as EU patent expiry nears
The BMS-Pfizer alliance has dominated the anticoagulant drug market, earning approximately $82.6bn in revenue since 2011.
Comment & Opinion
The new safety mandate driving AI-ready pharmacovigilance
When trillion‑member libraries meet physics: what diversity really means
UK–US zero‑tariff deal pricing reforms position UK as global hub for new medicines
JPM26: Immunocore Signals Entry into type 1 diabetes
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
Transformative arrival of oral weight loss medicines in the US
JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As
